Motif Neurotech wins FDA clearance for first human trial of a wireless brain implant targeting treatment-resistant depression in the U.S.
A tiny brain implant, no bigger than a blueberry, is moving from lab concept to human testing in the United States. Motif Neurotech has secured clearance from the U.S. Food and Drug Administration to begin its first clinical trial targeting treatment-resistant depression.
The decision marks a key step for a company aiming to bring engineering-driven solutions into mainstream mental health care. Nearly 3 million Americans live with forms of depression that do not respond to standard treatments. Motif’s approach focuses on directly interacting with neural circuits rather than relying only on drugs or talk therapy. The trial will test whether targeted electrical stimulation can improve outcomes where other methods have failed.
Minimally invasive brain deviceThe company’s device, called Digitally programmable Over-brain Therapeutic , delivers electrical stimulation to brain circuits linked to depression. Unlike traditional implants, DOT does not penetrate brain tissue. Surgeons place it in the skull above the dura, reducing the risks tied to invasive neurosurgery. Motif engineered the system to run wirelessly, eliminating the need for implanted batteries or wired connections.
The compact design aims to simplify procedures and improve patient comfort. Engineers also built the system to allow precise, programmable stimulation over time.
“The goal for this technology is that it would be the mental health equivalent of a continuous glucose monitor for diabetes,” said Jacob Robinson, professor at Rice University and co-founder and CEO of Motif. “What has been really special for me personally on this journey is to be able to work all the way from a concept through the process of research and development funded by the federal government at Rice, and take that into a product that is going to affect people’s lives for the better.
”Clinical trial across US centersThe early feasibility study will enroll adults whose depression has not improved after trying multiple therapies. Researchers will evaluate safety, device performance, and early signs of effectiveness. The study represents the first real-world test of the DOT system in patients. Several leading medical institutions will take part in the trial, including Baylor College of Medicine and Massachusetts General Brigham, along with other major centers across the country.
These collaborations aim to ensure rigorous data collection and diverse patient representation. Motif obtained its investigational device exemption in just four years after founding. That pace stands out in the brain-computer interface field, where development timelines often stretch much longer due to regulatory and technical hurdles. Federal push for precision careMotif also joined a federal initiative focused on advancing behavioral health treatments through better data.
The program, led by the Advanced Research Projects Agency for Health, supports faster validation of emerging therapies. Through this effort, Motif will gather additional patient data alongside its clinical trial. Researchers aim to identify which individuals respond best to neuromodulation and how treatment effects evolve over time.
“The idea with this funding is to support a number of teams who have rapid-acting interventions for a mental health condition and to collect additional data to help determine with greater precision whether a treatment is working, how it is working and which patients are benefitting most from which course of treatment,” Robinson said. The technology builds on more than a decade of research from teams at Rice and collaborating institutions.
Federal agencies, including the National Institutes of Health and the Defense Advanced Research Projects Agency, supported early work. The project reflects a broader push to translate advances in neuroscience and engineering into practical therapies. If you or someone you know is struggling with depression, support is available, and you don’t have to face it alone. U.S.: Call or text 988 . UK: Call 116 123 .
Brain Computer Interface Brain Implant Clinical Trials FDA Approval Motif Neurotech Neuromodulation
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The Most Underrated Story From Oregon's Spring Game Is ClearSpring games are not just about evaluating quarterbacks, testing young players or giving fans a show. For Oregon this one also doubled as a live rehearsal for two new coordinators stepping into major roles.
Read more »
Keskine LED Face Mask Pro: Salon-Grade Skincare Now on Sale with Double DiscountThe FDA-cleared Keskine LED Light Therapy Face Mask Pro is currently available with a significant discount, offering a powerful and convenient at-home solution for various skin concerns like acne, wrinkles, and dullness.
Read more »
A Brain Implant for Depression Is About to Be Tested in HumansWhile many brain-computer interface companies are focused on helping paralyzed people communicate, Motif Neurotech is targeting mental health disorders.
Read more »
Bonbons sold in 40 states recalled over undeclared walnutsA popular gourmet chocolate product sold across the United States is being recalled after a labeling error failed to disclose the presence of walnuts, according to the Food & Drug Administration (FDA).
Read more »
Netanyahu appears in court in corruption trial for first time since Iran war beganThe Israeli prime minister is scheduled to testify in Case 4000, in which he is accused of bribery, fraud and breach of trust, according to the prosecutor's office.
Read more »
First Gene Therapy for Genetic Hearing Loss Gains FDA ApprovalIn a historic leap for medical science, the U.S. Food and Drug Administration (FDA) has greenlit the first-ever gene therapy to treat a rare form of inherited deafness.
Read more »